HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
4317studies shown
Showing 3,565-3,576 of 4,317
Drug study icon
RecruitingNCT07680946

Ublituximab for treatment-resistant schizophrenia: safety and symptoms

About this title

Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia

Read the official source — NCT07680946
What is this study about?

Researchers are studying Ublituximab to find out how it affects psychotic symptoms in people with schizophrenia.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–60
Countries
United States
Sponsor
TG Therapeutics, Inc.
Drug study icon
RecruitingNCT05303064

Weight changes with olanzapine-samidorphan or olanzapine in young people with schizophrenia or bipolarity

About this title

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

Read the official source — NCT05303064
Official study title

A Phase 3, Randomized, Double-Blind, 52-Week Study of OLZ/SAM vs Olanzapine to Evaluate Weight Gain as Assessed by Change in BMI Z-Score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder (ENLIGHTEN-Youth)

Multiple locations, including Dothan
Bipolarity, SchizophreniaMedication studyAges 10–17
Countries
United States, Argentina, Brazil, + 2 others
Sponsor
Alkermes, Inc.
Drug study icon
RecruitingACTRN12609000011280

Sub-chronic administration of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers: drug initiation effects and the role of serotonin in experimental anxiety.

Official study title

The effect in healthy volunteers of administration of the selective serotonin reuptake inhibitor escitalopram (10 mg/day for 3 weeks) vs. placebo on drug initiation effects and experimentally-induced anxiety.

Location not clearly listed
AnxietyInterventional studyAges 18–65
Countries
Sponsor
University of Western Australia
Drug study icon
RecruitingNCT07247968

Esketamine with electroconvulsive therapy for severe depression in adolescents

About this title

Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study

Read the official source — NCT07247968
Official study title

Clinical and Mechanistic Study of Subanesthetic-dose Esketamine in Modified Electroconvulsive Therapy for Adolescents With Severe Depression

In Chongqing
DepressionMedication studyAges 13–17
Countries
China
Sponsor
Min Su
Drug study icon
RecruitingNCT07639359

Ketamine infusions for depressive symptoms in intensive care

About this title

Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients

Read the official source — NCT07639359
What is this study about?

Researchers are comparing Ketamine (0.5 mg/kg) and placebo to find out how the approaches affect depression symptoms in people with depression.

Multiple locations, including Jacksonville
DepressionMedication studyAges 18–99
Countries
United States, Argentina
Sponsor
Hospital Italiano de Buenos Aires
Drug study icon
RecruitingEUCTR 2021-001817-35

Suboxone compared with methadone for opioid use and chronic pain

About this title

Treatment of opioid dependency in patients with chronic pain: a comparative study between suboxone and methadone. Behandeling van opiaatafhankelijkheid bij pijn: een vergelijkende studie met suboxone en methadon.

Read the official source — 2021-001817-35
Official study title

Suboxone (buprenorphine/naloxone) versus methadone opioid rotation in patients with escalated opioid use and chronic pain: a randomized trial.

Original registry wording; source language not specified.

This study transferred to CTIS. HopeStage uses that newer record for the displayed status. A country's status does not guarantee that an individual site accepts participants.

In Nijmegen
AddictionHistorical research record
Countries
Netherlands
Sponsor
Radboud University Medical Center
Behavioral study icon
RecruitingNCT04366531

Transition support for veterans leaving prison

About this title

Successful Transitions and Reintegration Tools for Veterans (START-VETS)

Read the official source — NCT04366531
Official study title

Development of a Psycho-social Transition Program and Transition Assessment Tools for Veterans With Mental Illness and/or Substance Use Disorders Leaving Prison

In Dallas
AddictionBehavioural studyAges 18+
Countries
United States
Sponsor
VA Office of Research and Development (Government agency)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.